OPKO Diagnostics, a division of OPKO Health and Sony DADC have signed a supply deal for high volume production of a key component of the OPKO Sangia microfluidic cassette, designed to perform quantitative immunoassays from a finger-stick blood sample on the Claros1 in-office analyzer.
The test results are reported in the physician’s office in 10 minutes. The first two OPKO Sangia tests are for total prostate specific antigen (Total PSA) and Total Testosterone.
Sony DADC BioSciences is using its Salzburg facility in Austria to manufacture to OPKO Diagnostics’ specifications.
OPKO Diagnostics president David Okrongly said the company is pleased to be partnered with Sony DADC, a world leader in high precision consumable manufacturing, for production of Sangia technology components.
"It is critical to us that Sony DADC also meets the regulatory demands of our in vitro diagnostic products and is manufacturing to the ISO 13485 quality standard," Okrongly added.
Sony DADC BioSciences division senior vice president Dr Chris Mauracher said the company is delighted to have gained the trust of the team at OPKO Diagnostics.
"Based on our extensive experience in translating polymer science into robust manufacturing processes, we look forward to supplying the Sangia microfluidic components to OPKO Diagnostics as they grow their global business footprint," Dr Mauracher added.